Focus: Pharming Group is a Netherlands-based public biotechnology company specializing in biologics, with a highly concentrated revenue model centered on a single commercial-stage product.
Profile data last refreshed 20h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Pharming Group to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pharming Group
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pharming Group's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Only approved product and sole revenue source; PI3K-delta inhibitor for rare immunodeficiency disorders with label-expansion potential in pediatric populations.
PHARMA Forecast — Price Target — Prediction for 2027 - TradingView
PHARMA Forecast — Price Target — Prediction for 2027 TradingView
High Growth Tech Stocks in Europe with Promising Potential - simplywall.st
High Growth Tech Stocks in Europe with Promising Potential simplywall.st
Top Cybin (HELP) Competitors 2026 - MarketBeat
Top Cybin (HELP) Competitors 2026 MarketBeat
FDA Accepts Pharming Group Application to Expand Joenja Use to Children Aged 4 to 11 - geneonline.com
FDA Accepts Pharming Group Application to Expand Joenja Use to Children Aged 4 to 11 geneonline.com
Pharming announces U.S. FDA acceptance of sNDA resubmission - GlobeNewswire
Pharming announces U.S. FDA acceptance of sNDA resubmission GlobeNewswire
Pharming secures novel EU approval for Joenja in activated PI3K delta syndrome - European Pharmaceutical Review
Pharming secures novel EU approval for Joenja in activated PI3K delta syndrome European Pharmaceutical Review
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Corrigendum to "Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry" [Clinical Immunology 283 (2025) 110632].
Natural history of clinical manifestations in activated phosphoinositide 3-kinase δ syndrome (APDS): Time-to-event analyses using the European Society for Immunodeficiencies-APDS registry.
Showing 5 of 10 publications